z-logo
open-access-imgOpen Access
Inhibition of Plasmodium Liver Infection by Ivermectin
Author(s) -
António M. Mendes,
Inês S. Albuquerque,
Marta Machado,
Joana Pissarra,
Patrícia Meireles,
Miguel Prudêncio
Publication year - 2016
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02005-16
Subject(s) - ivermectin , parasitemia , malaria , biology , parasite hosting , vector (molecular biology) , plasmodium (life cycle) , in vivo , immunology , plasmodium falciparum , virology , pharmacology , microbiology and biotechnology , recombinant dna , zoology , biochemistry , world wide web , computer science , gene
Avermectins are powerful endectocides with an established potential to reduce the incidence of vector-borne diseases. Here, we show that several avermectins inhibit the hepatic stage of Plasmodium infection in vitro Notably, ivermectin potently inhibits liver infection in vivo by impairing parasite development inside hepatocytes. This impairment has a clear impact on the ensuing blood stage parasitemia, reducing disease severity and enhancing host survival. Ivermectin has been proposed as a tool to control malaria transmission because of its effects on the mosquito vector. Our study extends the effect of ivermectin to the early stages of mammalian host infection and supports the inclusion of this multipurpose drug in malaria control strategies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom